New Cures Need
Exponential reductions in the cost of DNA sequencing, combined with the advanced computational methods of machine learning & artificial intelligence (ML/AI), will inevitably disrupt the costly & time-consuming process of finding cures for difficult-to-treat diseases. Haystack Sciences is at the forefront of this evolution.
Haystack’s proprietary methods for synthesizing, breeding, and analyzing large, diverse combinatorial chemical libraries encoded by unique DNA sequences (DNA-Encoded Libraries, or DELs) establishes a revolutionary, data-intensive platform for discovering new cures for difficult-to-treat disorders.
Haystack Sciences accelerates pharmaceutical development using
DNA-templated combichem libraries
Advanced computational methods for library characterization
An experimental algorithm (nDexer™) for compound ranking
Haystack Sciences Platform
Haystack Sciences’ DNA-Encoded Libraries couple synthetic chemistry with Darwinian selection to evolve drug candidates.
Haystack Sciences synthesizes some of the most diverse and drug-like chemical libraries on earth. Our cutting edge chemical techniques access a market-leading array of chemistries and maximize library yields.
Haystack Sciences’ novel methods enable the selection of molecules possessing multiple properties required of good drugs, including affinity and selectivity, as well as key metabolic and pharmacokinetic properties.
Haystack’s innovative selection technology captures rich data correlating chemical structures to activities. This novel technology rank orders compounds by their activities, informing and speeding drug discovery.
DNA is at The Heart of Biology
By connecting DNA directly to chemistry, Haystack’s technology enables the rapid discovery and refinement of new therapeutic molecules through molecular breeding.
What's more, Haystack’s experimental algorithm, nDexer™, is capable of unprecedented data extraction from DELs of all scales.
The People Behind Haystack Sciences
Haystack have deep expertise in technology development and commercialization.
Eddie Ray Watts